NO20084380L - Neuromedin U-reseptoragonister og anvendelser derav - Google Patents

Neuromedin U-reseptoragonister og anvendelser derav

Info

Publication number
NO20084380L
NO20084380L NO20084380A NO20084380A NO20084380L NO 20084380 L NO20084380 L NO 20084380L NO 20084380 A NO20084380 A NO 20084380A NO 20084380 A NO20084380 A NO 20084380A NO 20084380 L NO20084380 L NO 20084380L
Authority
NO
Norway
Prior art keywords
neuromedin
receptor agonists
applications
obesity
diabetes
Prior art date
Application number
NO20084380A
Other languages
English (en)
Norwegian (no)
Inventor
Donald J Marsh
Antonello Pessi
Maria A Bednarek
Elisabetta Bianchi
Paolo Ingallinella
Andrea M Peier
Original Assignee
Angeletti P Ist Richerche Bio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angeletti P Ist Richerche Bio filed Critical Angeletti P Ist Richerche Bio
Publication of NO20084380L publication Critical patent/NO20084380L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C07K14/43—Sweetening agents, e.g. thaumatin, monellin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • Botany (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20084380A 2006-03-20 2008-10-17 Neuromedin U-reseptoragonister og anvendelser derav NO20084380L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78393306P 2006-03-20 2006-03-20
PCT/US2007/006635 WO2007109135A2 (en) 2006-03-20 2007-03-16 Neuromedin u receptor agonists and uses thereof

Publications (1)

Publication Number Publication Date
NO20084380L true NO20084380L (no) 2008-12-16

Family

ID=38522976

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084380A NO20084380L (no) 2006-03-20 2008-10-17 Neuromedin U-reseptoragonister og anvendelser derav

Country Status (15)

Country Link
US (2) US20070244048A1 (de)
EP (1) EP1999143B1 (de)
JP (1) JP2009530379A (de)
KR (1) KR20090005329A (de)
CN (1) CN101443356A (de)
AT (1) ATE516300T1 (de)
AU (1) AU2007227510A1 (de)
BR (1) BRPI0708943A2 (de)
CA (1) CA2647027A1 (de)
IL (1) IL193996A0 (de)
MX (1) MX2008012055A (de)
NO (1) NO20084380L (de)
RU (1) RU2008141280A (de)
WO (1) WO2007109135A2 (de)
ZA (1) ZA200807789B (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050090420A (ko) 2002-12-26 2005-09-13 다케다 야쿠힌 고교 가부시키가이샤 메타스틴 유도체 및 이의 용도
AR049938A1 (es) 2004-06-25 2006-09-13 Takeda Pharmaceutical Derivados de metastina y utilizacion de los mismos
US8404643B2 (en) 2005-12-22 2013-03-26 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
JO3048B1 (ar) 2006-10-25 2016-09-05 Takeda Pharmaceuticals Co مشتقات متاستين واستخدامها
US8309522B2 (en) 2007-02-05 2012-11-13 Amylin Pharmaceuticals, Llc Neuromedin and FN-38 peptides for treating psychiatric diseases
US20100190717A1 (en) * 2007-09-11 2010-07-29 Dorian Bevec Use of melanin concentrating hormone and met-enkephalin as therapeutic agents
CA2701612A1 (en) * 2007-10-05 2009-04-09 Takeda Pharmaceutical Company Limited Neuromedin u derivative
US20090104210A1 (en) * 2007-10-17 2009-04-23 Tota Michael R Peptide compounds for treating obesity and insulin resistance
PT2314609T (pt) * 2008-07-30 2017-03-06 Takeda Pharmaceuticals Co Derivado de metastina e sua utilização
US20110294735A1 (en) * 2008-11-05 2011-12-01 Merck Sharp & Dohme Corp. Mechanism of neuromedin u action and uses thereof
JO2870B1 (en) 2008-11-13 2015-03-15 ميرك شارب اند دوهم كورب Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes
WO2010067233A1 (en) 2008-12-08 2010-06-17 Pfizer Inc. 1,2,4 triazolo [4, 3 -a] [1,5] benzodiazepin-5 (6h) -ones as agonists of the cholecystokinin-1 receptor (cck-ir)
WO2010116752A1 (ja) * 2009-04-08 2010-10-14 武田薬品工業株式会社 ニューロメジンｕ誘導体
WO2010138343A1 (en) * 2009-05-27 2010-12-02 Merck Sharp & Dohme Corp. Neuromedin u receptor agonists
WO2011005611A1 (en) * 2009-07-09 2011-01-13 Merck Sharp & Dohme Corp. Neuromedin u receptor agonists and uses thereof
IN2012DN00721A (de) 2009-09-02 2015-06-19 Merck Sharp & Dohme
CN102812037A (zh) * 2009-10-30 2012-12-05 特兰齐姆制药公司 大环生长素释放肽受体拮抗剂和反向激动剂及其使用方法
US20120219538A1 (en) * 2009-11-02 2012-08-30 Therapeomic Ag Stabilized protein formulations and use thereof
US8853212B2 (en) 2010-02-22 2014-10-07 Merck Sharp & Dohme Corp Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes
WO2011146358A1 (en) 2010-05-21 2011-11-24 Merck Sharp & Dohme Corp. Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
JP2013209295A (ja) 2010-10-13 2013-10-10 Takeda Chem Ind Ltd ペプチド誘導体
WO2012106581A1 (en) * 2011-02-03 2012-08-09 The University Of Chicago Fxr inhibitor, bile acid sequestrant as combination therapy for cholesterol reduction
IN2014DN09640A (de) 2012-04-16 2015-07-31 Kaneq Pharma Inc
EP2842965A1 (de) 2013-09-03 2015-03-04 Gubra ApS Neuromedin-U-Analoga mit Serumalbumin zur Bindung von Aminosäurerückständen
US10286078B2 (en) 2013-09-13 2019-05-14 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
CA2933701C (en) 2013-12-18 2022-05-31 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
CN106084001B (zh) * 2016-04-21 2019-05-24 上海天慈生命科学发展有限公司 一类阿片和神经肽ff受体的多靶点肽类分子及其制备和应用
MX2019006886A (es) 2016-12-13 2019-10-30 Limm Therapeutics Sa Métodos para tratar enfermedades asociadas con células linfoides innatas del grupo 2 (ilc2).
WO2018135641A1 (ja) * 2017-01-20 2018-07-26 学校法人東京薬科大学 ペプチドもしくはその薬学的に許容される塩、またはそれらのプロドラッグ
WO2018135642A1 (ja) * 2017-01-20 2018-07-26 学校法人東京薬科大学 ペプチド、その薬学的に許容される塩、またはそれらのプロドラッグ、およびそれらの用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1553101A (en) * 1999-11-29 2001-06-12 Takeda Chemical Industries Ltd. Screening method

Also Published As

Publication number Publication date
US20070244048A1 (en) 2007-10-18
RU2008141280A (ru) 2010-04-27
US20100075907A1 (en) 2010-03-25
MX2008012055A (es) 2008-10-02
WO2007109135A3 (en) 2008-04-03
CA2647027A1 (en) 2007-09-27
ATE516300T1 (de) 2011-07-15
EP1999143A2 (de) 2008-12-10
BRPI0708943A2 (pt) 2011-06-14
JP2009530379A (ja) 2009-08-27
ZA200807789B (en) 2009-12-30
IL193996A0 (en) 2011-08-01
AU2007227510A1 (en) 2007-09-27
KR20090005329A (ko) 2009-01-13
WO2007109135A2 (en) 2007-09-27
EP1999143B1 (de) 2011-07-13
CN101443356A (zh) 2009-05-27

Similar Documents

Publication Publication Date Title
NO20084380L (no) Neuromedin U-reseptoragonister og anvendelser derav
DK2367793T3 (da) GPR120-receptoragonister og anvendelser deraf.
AU2007221366A8 (en) Oxyntomodulin derivatives
CL2008002042A1 (es) Compuestos derivados de heterociclos nitrogenados enlazados; y su uso en el tratamiento de la diabetes y desordenes metabolicos.
BRPI0915282A2 (pt) agonistas mistos baseados no gip para o tratamento de distúrbios metabólicos e obesidade
NO20091734L (no) Glucagonreseptorantagonistforbindelser, preparater inneholdende slike forbindelser, og metoder for anvendelse
TN2012000302A1 (en) Oxyntomodulin peptide analogue
NO20080010L (no) GPCR-agonister
EP1993560A4 (de) Cannabinoid-rezeptor-antagonisten / inverse agonisten zur behandlung von übergewicht
DK1984345T3 (da) Benzoxaziner og beslægtede nitrogenholdige heterobicykliske forbindelser, der kan anvendes som mineralcorticoidreceptormodulerende midler
GB2465677B (en) Non-systemic delivery of satiogens for use in the treatment of obesity and/or diabetes
EA200900796A1 (ru) Пиперидиновые агонисты gpcr
NO20092034L (no) Kjemiske forbindelser og anvendelser
EA200900880A1 (ru) Пиперидиновые агонисты gpcr
CL2008003847A1 (es) Compuestos derivados de 6-fenilpirazin-2-carboxamida y 6-fenilpirazin-2-carbotioamida, inhibidores de dgat-1; composicion farmaceutica; y su uso en el tratamiento de la diabetes mellitus y obesidad.
DK2170930T3 (da) Agonister af guanylatcyclase, anvendelige til behandlingen af gastrointestinale sygdomme, inflammation, cancer og andre sygdomme
NO20091700L (no) Florizinanaloger som inhibitorer av glukose-ko-transporter 2
DK2185164T3 (da) Sammensætning og terapeutisk antitumorvaccine
EA200802184A1 (ru) Фармацевтические композиции с ингибиторами dpp iv
MX2009011359A (es) Derivados de pirimidinona y sus metodos de uso.
DK2077976T3 (da) Bioaktiv, rutheniumholdig belægning og indretning
DK1901731T3 (da) Niacinreceptoragonister, sammensætninger indeholdende sådanne forbindelser og fremgangsmåder til behandling
EA200900878A1 (ru) Пиперидиновые агонисты gpcr
TN2012000002A1 (en) Gpr119 agonists
EP1841781A4 (de) Verwendung von il-22 zur behandlung von stoffwechselstörungen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application